- Home
- CGNT vs CRGX Comparison
CGNT vs CRGX Comparison
Compare CGNT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- CRGX
- Stock Information
- Founded
- CGNT 2020
- CRGX 2021
- Country
- CGNT Israel
- CRGX United States
- Employees
- CGNT N/A
- CRGX N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- CRGX
- Sector
- CGNT Technology
- CRGX
- Exchange
- CGNT Nasdaq
- CRGX Nasdaq
- Market Cap
- CGNT 669.2M
- CRGX 190.0M
- IPO Year
- CGNT N/A
- CRGX 2023
- Fundamental
- Price
- CGNT $8.93
- CRGX $4.46
- Analyst Decision
- CGNT Hold
- CRGX Hold
- Analyst Count
- CGNT 1
- CRGX 7
- Target Price
- CGNT N/A
- CRGX $4.67
- AVG Volume (30 Days)
- CGNT 450.8K
- CRGX 502.9K
- Earning Date
- CGNT 06-11-2025
- CRGX 08-11-2025
- Dividend Yield
- CGNT N/A
- CRGX N/A
- EPS Growth
- CGNT N/A
- CRGX N/A
- EPS
- CGNT N/A
- CRGX N/A
- Revenue
- CGNT $363,466,000.00
- CRGX N/A
- Revenue This Year
- CGNT $14.94
- CRGX $57.81
- Revenue Next Year
- CGNT $9.57
- CRGX N/A
- P/E Ratio
- CGNT N/A
- CRGX N/A
- Revenue Growth
- CGNT 12.58
- CRGX N/A
- 52 Week Low
- CGNT $6.21
- CRGX $3.00
- 52 Week High
- CGNT $11.66
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- CGNT 41.91
- CRGX 57.89
- Support Level
- CGNT $9.08
- CRGX $4.09
- Resistance Level
- CGNT $9.49
- CRGX $4.51
- Average True Range (ATR)
- CGNT 0.30
- CRGX 0.18
- MACD
- CGNT -0.02
- CRGX 0.00
- Stochastic Oscillator
- CGNT 49.13
- CRGX 77.18
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.